Shanghai Henlius Initiates Phase II Study of HLX22 in HER2 Low Breast Cancer
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced the first patient dosing in a...
GSK’s Blenrep Approved by UK MHRA for Multiple Myeloma Treatment
UK-based pharmaceutical giant UK-based pharmaceutical company GlaxoSmithKline (GSK, NYSE: GSK) has announced the receipt of...
Salubris Pharma’s YOLT-101 Gene Editing Drug Accepted for NMPA Review
China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) announced that the National Medical Products Administration...
Hansoh’s HS-20093 ADC Earns BTD for Advanced NSCLC from China’s NMPA
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that China’s National Medical Products...
Akeso Biopharma Partners with Virogin to Test Ivonescimab and VG201 in Colorectal Cancer Trial
China-based Akeso Biopharma (HKG: 9926) has entered into a clinical collaboration with Virogin Biotech Co.,...
Chengdu Kanghong Gains NMPA Approval for KH815 in Advanced Solid Tumors
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd. (SHE: 002773) has received clinical trial approval from...
Avistone’s Vebreltinib and PLB1004 Receive CDE Breakthrough Therapy Designation for NSCLC
China’s Center for Drug Evaluation (CDE) has granted breakthrough therapy designation (BTD) to Beijing Avistone...
Shanghai Pharmaceuticals’ RMB 4.66 Billion M&A Fund Completes AMAC Registration
China’s Shanghai Pharmaceuticals Holding Ltd (SPH, HKG: 2607, SHA: 601607) has announced the completion of...
Zhaoke Ophthalmology Signs Distribution Agreements with Thailand’s Interpharma for Myopia and Presbyopia Treatments
China-based Zhaoke Ophthalmology Ltd (HKG: 6622) has announced the signing of three distribution and supply...
Eisai and Biogen Win EU Approval for Leqembi in Early Alzheimer’s Disease
Eisai Co., Ltd. (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) jointly announced that they have...
Jiangsu Wuzhong Pharma Faces Forced Delisting After CSRC Investigation
China-based Jiangsu Wuzhong Pharmaceutical Group Corp. (SHA: 600200) has disclosed a potential forced delisting from...
Sichuan Biokin’s BL-M09D1 ADC Receives NMPA Clinical Trial Clearance for Solid Tumors
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that its antibody-drug conjugate (ADC) BL-M09D1...
Da Ren Tang Sells Stake in Tianjin Shike to Haleon for RMB 1.623 Billion
Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd. (SHA: 600329), a traditional Chinese medicine (TCM)...
Akeso Biopharma Partners with Virogin to Test Ivonescimab and VG201 in Colorectal Cancer Trial
China-based Akeso Biopharma (HKG: 9926) has entered into a clinical collaboration with Virogin Biotech Co.,...
Berry Genomics Collaborates with Beijing Children’s Hospital on Newborn Birth Defects Screening Project
China-based genomics testing company Berry Genomics (SHE: 000710) has entered into a project achievement translation...
Trump Orders HHS to Reduce Drug Prices, Revamp Medicare Negotiation Program
President Donald Trump issued a new Executive Order aimed at reducing drug prices for American...
Galderma Launches Sculptra in China as First Regenerative Biostimulator
Switzerland-based skin care specialist Galderma officially launched Sculptra in China this week, marking the first...
Easton Pharma’s EP-9001A Shows Promising Results in Phase Ib for Bone Metastasis Cancer Pain
Chengdu-based Easton Pharmaceutical Co., Ltd (SHA: 688513) has announced preliminary statistical analysis results from the...
Edwards Lifesciences Gains EU CE Mark for SAPIEN M3 Mitral Valve System
US medical device giant Edwards Lifesciences Corporation (NYSE: EW) has announced that it has received...
InnoCare Pharma’s Zurletrectinib NDA Accepted by China’s CDE for TRK Fusion Cancers
Beijing-based biopharmaceutical company InnoCare Pharma (HKG: 9969, SHA: 688428) has announced that China’s Center for...